NasdaqCM - Delayed Quote • USD
Abeona Therapeutics Inc. (ABEO)
At close: April 19 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.56 | -0.6 | -1.92 | -1.1 |
| Low Estimate | -0.63 | -0.63 | -1.98 | -2.43 |
| High Estimate | -0.5 | -0.58 | -1.86 | 0.23 |
| Year Ago EPS | -0.54 | -0.92 | -2.53 | -1.92 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | 250k | 250k | 17.85M | 71.1M |
| Low Estimate | -- | -- | 16M | 49.1M |
| High Estimate | 500k | 500k | 19.7M | 93.1M |
| Year Ago Sales | -- | -- | 3.5M | 17.85M |
| Sales Growth (year/est) | -- | -- | 410.00% | 298.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.58 | -0.68 | -0.53 | -0.47 |
| EPS Actual | -0.54 | -0.92 | -0.48 | -0.77 |
| Difference | 0.04 | -0.24 | 0.05 | -0.3 |
| Surprise % | 6.90% | -35.30% | 9.40% | -63.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.56 | -0.6 | -1.92 | -1.1 |
| 7 Days Ago | -0.56 | -0.6 | -1.92 | -1.1 |
| 30 Days Ago | -0.53 | -0.55 | -1.76 | -0.73 |
| 60 Days Ago | -0.51 | -0.5 | -1.71 | -0.36 |
| 90 Days Ago | -0.51 | -0.5 | -1.71 | -0.36 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ABEO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -3.70% | -- | -- | 1.60% |
| Next Qtr. | 34.80% | -- | -- | 10.50% |
| Current Year | 24.10% | -- | -- | 5.20% |
| Next Year | 42.70% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 8/24/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 7/13/2023 |
| Reiterates | Alliance Global Partners: Buy | 5/24/2023 |
| Maintains | SVB Leerink: Market Perform | 11/14/2022 |
| Maintains | Cantor Fitzgerald: Overweight | 11/8/2022 |
| Maintains | SVB Leerink: Market Perform | 8/11/2022 |
Related Tickers
DAWN Day One Biopharmaceuticals, Inc.
14.96
-5.02%
XFOR X4 Pharmaceuticals, Inc.
1.2600
+5.00%
KRYS Krystal Biotech, Inc.
158.53
-3.32%
ADAP Adaptimmune Therapeutics plc
0.9767
+8.72%
RVPH Reviva Pharmaceuticals Holdings, Inc.
3.0200
0.00%
ZVRA Zevra Therapeutics, Inc.
4.5200
+0.44%
LPTX Leap Therapeutics, Inc.
2.8000
-5.41%
VRNA Verona Pharma plc
15.72
-2.36%
CRDF Cardiff Oncology, Inc.
4.3500
-0.46%
AFMD Affimed N.V.
5.15
+1.58%